• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Trevena Inc. filed SEC Form 8-K: Leadership Update

    11/27/24 4:05:28 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRVN alert in real time by email
    false 0001429560 0001429560 2024-11-26 2024-11-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): November 26, 2024

     

     

    TREVENA, INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    (State or other jurisdiction of incorporation)

     

    001-36193   26-1469215
    (Commission
    File No.)
        (IRS Employer
    Identification No.)

     

     

    955 Chesterbrook Boulevard, Suite 110

    Chesterbrook, PA 19087

    (Address of principal executive offices and zip code)

     

    Registrant’s telephone number, including area code: (610) 354-8840

     

    Not applicable

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
      
    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
      
    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
      
    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  Trading Symbol(s)  Name of each exchange on which
     registered
    Common Stock, $0.001 par value  TRVN  OTC Pink Open Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Departures and Appointments of Certain Officers

     

    On November 26, 2024, the Board of Directors (the “Board”) of Trevena, Inc. (the “Company”) designated Katrine Sutton as the Company’s principal financial officer and principal accounting officer, effective November 26, 2024. As a result of this designation, Barry Shin will no longer serve as the Company’s principal financial officer or principal accounting officer, effective November 26, 2024. Mr. Shin’s replacement was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

     

    Ms. Sutton, age 48, has served as the Company’s Vice President, Finance Planning and Analysis since July 2019. Prior to that, Ms. Sutton served as Vice President, Finance and Accounting with Synergy Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal therapies, from December 2015 to July 2019. Ms. Sutton holds a Bachelor of Science in Accounting from the University of Richmond and is a Certified Public Accountant.

     

    There are no arrangements or understandings between Ms. Sutton and any other person pursuant to which Ms. Sutton was designated as principal financial officer and principal accounting officer. Ms. Sutton has no family relations with any directors or executive officers of the Company. There are no transactions to which the Company is a party and in which Ms. Sutton has a material interest that is required to be disclosed under Item 404(a) of Regulation S-K.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        TREVENA, INC.
         
    Date: November 27, 2024 By: /s/ Carrie Bourdow
        Carrie Bourdow
        Acting Chief Executive Officer and Principal Executive Officer

     

     

     

    Get the next $TRVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRVN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TRVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Trevena Reports Third Quarter 2024 Results and Provides Business Update

      CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended September 30, 2024 and provided an overview of its recent operational updates. Third Quarter 2024 and Recent Corporate Updates $2 million Non-Dilutive Financing Tranche. In July 2024, the Company announced receipt of a non-dilutive, $2 million tranche in connection with an amendment (the "Amendment") to its existing ex-US royalty financing with R-Bridge Healthcare Fund ("R-Bridge"). The Compa

      11/7/24 7:01:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevena Announces Receipt of Nasdaq Delisting Notification

      CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that on October 4, 2024 the Company received notice that the Nasdaq Hearings Panel (the "Panel") had determined to delist the Company's common stock from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with the minimum stockholder's equity requirement under Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard Rule"). As previously disclosed, the Panel had provided the Company until October 2, 2024, to regain comp

      10/4/24 4:05:00 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevena Announces Reverse Stock Split

      CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the "Amendment") to effect a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective at 12:01 a.m. ET on Tuesday, August 13, 2024. Trevena's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "TRVN" and will begin trading on a split-adjusted basis when the market opens on Tu

      8/8/24 4:05:00 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Trevena Inc.

      SC 13G/A - TREVENA INC (0001429560) (Subject)

      11/14/24 4:43:11 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Trevena Inc.

      SC 13G - TREVENA INC (0001429560) (Subject)

      9/19/24 4:09:55 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Trevena Inc. (Amendment)

      SC 13G/A - TREVENA INC (0001429560) (Subject)

      2/14/24 2:34:30 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Sutton Katrine claimed ownership of 942 shares (SEC Form 3)

      3 - TREVENA INC (0001429560) (Issuer)

      12/6/24 4:39:03 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acting CMO Demitrack Mark covered exercise/tax liability with 885 shares, decreasing direct ownership by 7% to 11,363 units (SEC Form 4)

      4 - TREVENA INC (0001429560) (Issuer)

      10/10/24 5:08:47 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acting COO and CFO Shin Barry covered exercise/tax liability with 806 shares, decreasing direct ownership by 7% to 11,543 units (SEC Form 4)

      4 - TREVENA INC (0001429560) (Issuer)

      10/10/24 5:07:55 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Trevena

      Oppenheimer initiated coverage of Trevena with a rating of Market Perform

      3/15/21 7:02:03 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Trevana

      Oppenheimer initiated coverage of Trevana with a rating of Perform

      3/15/21 6:50:29 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors

      CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Corrigan, M.D. has been appointed to the Company's Board of Directors, effective July 18 2023. "We are pleased to welcome Mark to Trevena's Board of Directors," said Carrie Bourdow, Trevena's President and CEO. "Mark has over 30 years of experience in the life sciences industry and broad neuroscience expertise. He will be an invaluable member of the Board and guide to the management team as we continue to execute on our corporate

      7/20/23 7:00:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Imvax Appoints John M. Limongelli as Chief Legal Officer

      Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of John M. Limongelli as the Company's Chief Legal Officer effective September 16, 2021. "John's breadth of experience in the biopharma industry, his deep technical acumen, and his expertise at helping build strong corporate practices will be of invaluable benefit to our leadership team," said John Furey, Chief Executive Officer. "As we work to expand our platform to address a variety of solid tumors, John's expertise will be an essential part of the development of these assets." Mr. Limongelli is an accomplished executive officer and lawyer with near

      9/16/21 8:00:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVN
    SEC Filings

    See more
    • Trevena Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - TREVENA INC (0001429560) (Filer)

      5/15/25 8:09:22 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Trevena Inc.

      25-NSE - TREVENA INC (0001429560) (Subject)

      4/8/25 9:20:54 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-K filed by Trevena Inc.

      NT 10-K - TREVENA INC (0001429560) (Filer)

      3/31/25 4:01:19 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVN
    Financials

    Live finance-specific insights

    See more
    • Trevena Reports Third Quarter 2023 Results and Provides Business Update

      Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement Company reported favorable safety and tolerability data from TRV045 POC studies Three abstracts for OLINVYK presented at American Society of Anesthesiologists (ASA) Conference $15 million tranche from ex-US royalty-based financing agreement received in September Company to host conference call today, November 14, 2023 at 8:00 a.m. ET CHESTERBROOK, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for pat

      11/14/23 7:00:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023

      CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the third quarter ended September 30, 2023, prior to the market open on Tuesday, November 14, 2023. The Company will host a conference call and webcast with the investment community at 8:00 a.m. ET that same day, featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Mark Demitrack, M.D., SVP and Chief Medical Officer, and Barry Shin, SVP and Chief Financial Office

      11/9/23 7:00:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update

      $15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena's partner in China New OLINVYK respiratory data from VOLITION ~200 patient real-world outcomes study, using continuous respiratory monitoring, expected 3Q 2023 Three OLINVYK abstracts accepted for presentation at upcoming American Society of Anesthesiologists Meeting in 4Q 2023 Company to participate in upcoming HC Wainwright conference (September 11-13) Company to Hold Conference Call on Wednesday, September 6 at 8 a.m. Eastern Time to discuss TRV045 Proof-of-Concept Data CHESTERBROOK, Pa., Sept. 06, 2023 (GLOBE NEWSWI

      9/6/23 7:01:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care